</s><s><s><s> human papillomavirus is an emerging and zoonotic zoonosis that is endemic to the united states. 
 the estimated lifetime probability of acquiring this virus is 1 in 10,000,000, and it is associated with a lifetime risk of acquiring 1 in 1,500,000 new cases of human hepatitis b and c virus infections. in 2014, the national center for immunization and respiratory diseases ( ncidc ) and the center for emerging and viral infections ( cevd ) of the us department of health and human services issued updated recommendations of the advisory committee on immunization practices ( acip ) for the use of a 2-dose schedule for 9-valent and quadrivalent vaccine, respectively. in 2015, 
 updated recommendations were issued by the Advisory committee on Immunization practices for use of 9- and bivalent vaccines, respectively, for use in women aged 25 to 65 years. in 2016, updated recommendations from the acip were issued for use with the bivalent vaccine, and updated recommendations on use of quadrivalency vaccines were issued. </s>